The novel class of GLP-1 receptor and GIP dual medications, like tirzepatide, semaglutide, and the newly introduced retatrutide, offer promising advances in diabetes management . Although all three https://peptide-certificate-of-a323315.naomiblog.com/48124/retatrutide-a-thorough-examination